1,720,974 research outputs found
Improving cardiovascular health today to prevent heart failure tomorrow: the importance of a holistic approach
Full text linkThe changing landscape of heart failure: translating management into the modern era
No full textHeart failure (HF) is a complex clinical syndrome associated with high morbidity and mortality, accounting for approximately 2 % of total healthcare expenditures. Despite advances in pharmacological and device-based therapies, HF continues to affect over 70 million people globally, with an increasing prevalence driven by an aging population. The classification remains imperfect due to the pathophysiological complexity of the syndrome. Recent attention has focused on aetiological characterisation, particularly in non-ischaemic cardiomyopathies, where genetic testing may provide diagnostic, prognostic, and therapeutic insights. Left ventricular reverse remodeling (LVRR) and the recognition of HF with improved ejection fraction (HFimpEF) have highlighted the dynamic nature of HF and the importance of continued therapy despite apparent recovery. Guideline-directed medical therapy (GDMT), based on four foundational drug classes for HFrEF, has demonstrated significant benefit, yet its implementation remains suboptimal. For HFpEF, all effective drugs have however failed to reduce mortality. Device therapy, including implantable cardioverter-defibrillators (ICDs), cardiac resynchronisation therapy (CRT) and valve replacement offers additional benefit in select patients and may facilitate optimisation of medical therapy. New avenues such as multiomic profiling, gene therapy, and artificial intelligence (AI) are expanding our ability to phenotype HF, predict disease progression, and personalize treatment strategies. This viewpoint summarises the current understanding of HF, with an emphasis on the classification, aetiology, phenotypes and evidence-based management including newer therapies and their scope of use across the spectrum of LVEF
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity
Full text linkAimsTyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverseevents. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have beenused to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulnessof the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Associ-ation (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular riskin CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events(AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin.Methods and resultsA retrospective single-centre observational study was carried out on 58 patients (32 men and 26women; mean age ± SD: 59 ± 15 years) with CML treated with TKIs for a median period of 43 ± 31 months. Cardiological eval-uation was performed and cardiovascular risk was estimated with SCORE risk charts and with the new risk assessment toolproposed by HFA/ICOS. AEs were recorded. According to SCORE charts and the new HFA/ICOS risk stratification tool, respec-tively, 46% (Group A1) and 60% (Group A2) of patients were at high–very high risk, and 54% (Group B1) and 40% (Group B2) atlow–moderate risk. AEs were significantly more frequent in Group A1 than Group B1 (Pvalue<0.01) when considered overall;they were significantly more frequent in Group A2 than Group B2 either overall or considered individually. HFA/ICOS risk strat-ification tool was significantly more sensitive than SCORE (P<0.01) in identifying patients at higher risk of cardiovascular tox-icity. In addition, we did notfind AEs in patients pretreated with aspirin.ConclusionsThe new HFA/ICOS risk stratification model allows a more tailored cardiovascular risk stratification in patientswith CML and it is more sensitive than SCORE chart
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
- …
